重组人内皮抑素联合化疗治疗晚期NSCLC近期疗效观察

目的观察抗肿瘤新药重组人血管内皮抑素注射液联合化疗治疗晚期NSCLC的有效性和安全性。方法经组织学或细胞学确诊的Ⅳ期NSCLC患者34例接受重组人血管内皮抑素加常规化疗药物联合治疗，重组人血管内皮抑素剂量为（8.3~10）mg/m²，总量15 mg，加入生理盐水500 ml中缓慢静脉滴注（3～4）小时，滴注过程中给予心电监护，第1～14天连续给药；同时联合给予NCCN指南推荐的化疗药物治疗，每3周重复。按照RECIST标准评价近期客观疗效，按照NCI CTC 3.0版的分级标准评价药物毒性。治疗1周期后评价毒性，2周期后评价疗效。结果所有34例患者均可评价疗效，其中PR9例，SD19例，PD6例，临床有效率为26.47%（9/34），临床受益率为82.35%（28/34）,初治和复治患者的RR率为42.86%和15%（P<0.05）,CBR率分别为92.86%和75%（P<0.05），未出现严重不良反应。结论重组人内皮抑素联合化疗治疗晚期NSCLC耐受性好，可以提高化疗的有效率，用于一线治疗时疗效提高更为显著。

Rh-endostatin in Combination with Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Objective To evaluate the treatment efficacy and safety with the combination of rh endostatin(YH-16) and chemotherapy in patients with advanced non-small cell lung cancer(NSCLC). Methods 34 patients with advanced non small cell lung cancer confirmed by histopathology or cytopathology were administrated with YH-16 7.5mg/m² (day 1~14) and routine chemotherapy every 3 weeks.The dosage of (8.3~10)mg/m² (15mg/time) of rh endostatin solved in 500ml normal saline was slowly intravenously dropped for 3~4 hours from 1 to 14 days, repeated after 7days. The overall response and toxicity were observed. Results Totally, 34 patients were entered and all of these patients were evaluated.Partial response was observed in 9 patients,stable disease was observed in 19 patients and progressive disease was observed in 6 patients. Overall response rate was 26.47%（9/34）, Clinical benefit rate was 82.35%（28/34）.For the untreated patients and the pretreated patients,the response rate was 42.86% and 15%（P<0.05）, Clinical benefit rate was 92.86% and 75%（P<0.05）, respectively.No serious adverse event was observed. Conclusion The rh-endostatin combined with chemotherapy tends to show a better treatment efficacy than chemotherapy alone and is well tolerated in patients with advanced non small cell lung cancer patients,especially in the front line treatment.